Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Catalent Adds Two New Directors To Board
Prior to joining Catalent Pharma Mr Booth worked as president and chief operating officer of Medimmune, from 1998 through his retirement in 2003, and as a director from
Prior to joining Catalent Pharma Mr Booth worked as president and chief operating officer of Medimmune, from 1998 through his retirement in 2003, and as a director from
Bionas claimed that the technology allows for the analysis of cellular behavior in real-time without the use of any dyes or antibodies, thus avoiding the result being biased
CytRx has recruited its first patient in a Phase 2 proof-of-concept trial in patients with high-risk B-cell chronic lymphocytic leukemia (B-CLL), which is advancing towards the initiation of
Aspen’s solubility modeling technology, which was developed in collaboration with pharmaceutical companies, is said to provide Quality by Design (QbD) capabilities that help manufacturers comply with the latest
Tapentadol is a centrally acting oral analgesic that binds to mu-opioid receptors and inhibits norepinephrine reuptake. Although the exact mechanism of action is not known, these two mechanisms,
Reportedly, investigation of the compound continues in some areas of high unmet medical need, including cancer pain. Considering of reports of adverse events in osteoarthritis patients taking Tanezumab,
Rasilez, known as Tekturna in the US, works by directly inhibiting the activity of renin, an enzyme produced by the kidneys that starts a process in the renin-angiotensin-aldosterone
NIAID used a Selectivity Index (SI) to determine the effectiveness of a compound. The SI measures EC50 (50% virus-inhibitory (effective) concentration and EC90 (90%) cell inhibitory (cytotoxic) concentration
Under the terms of the agreement ELITech expects to initially purchase 8,333,334 shares of Corgenix common shares at $0.15 per share. Corgenix and ELITech will co-develop new tests
TBR-652 Phase II trial demonstrated that a 10-day course of once-daily TBR-652 monotherapy produced a median nadir decline from baseline in HIV viral load of up to 1.8